Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Finally, common infections are covered, as are HIV and AIDS; viral, bacterial, spirochetal, protozoal, and mycotic infections; physical agents; poisoning; cancer; genetic disorders; and complementary ...

Genital mycotic infections, pollakiuria, hypotension were more common with CANA 100 mg and 300 mg compared to placebo Slight higher incidence of urinary tract infections with CANA 300 than CANA ...